Gubra’s once-weekly obesity candidate was tied | Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection also linked to weight reduction.
Radella Pharmaceuticals’ MD-18 shows promise in Phase 1a results. (Credit: Bruno from Pixabay) Radella Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced topline results from its Phase 1a study of MD-18, an investigational treatment for obesity and diabetes. The study evaluated MD-18’s safety, tolerability, and pharmacokinetics. MD-18 targets protein-tyrosine phosphatase 1B (PTP1B), a therapeutic target supporting […]
Welcome to Herbology News!
At Herbology News, we’re dedicated to empowering you with knowledge and resources to help you lead a healthier life naturally.
Herbologynews @2024. All Rights Reserved.
Subscribe to receive fresh content, tips, and insights delivered straight to your inbox—never miss a post again!
